FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
78 letters match. Newest first.
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsGuangzhou Jiugong Research And Development Biotechnology Co., Ltd.
Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.
High risk -
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
DrugsFairyGene, Inc.
FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DrugsAlmon Healthcare Private Limited
Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DevicesDiasol, Inc.
Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.
High risk -
DrugsAQ USA Inc., d.b.a Ross Healthcare Inc.
FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsScientific Protein Laboratories, LLC
FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.
High risk -
FoodGracie's Kitchens, Inc.
FDA warns Gracie's Kitchens over Listeria on RTE produce food-contact surfaces and sanitation failures.
High risk -
DrugsChengdu Brilliant Biopharmaceutical Co., Ltd.
FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.
High risk -
DevicesLeMaitre Vascular, Inc.
LeMaitre Vascular's Artegraft graft plant in New Jersey drew an FDA warning letter for water, sterilization and recall-reporting failures.
High risk -
DrugsShiva Analyticals Private Limited
FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsBEO Pharma Inc. dba BEO Pharmaceuticals Inc.
FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsColgate-Palmolive/Tom's of Maine, Inc.
FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.
High risk -
DrugsChoice All Natural, Inc. dba Om Botanical
FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
FoodDonggang Wanrui Food Co., Ltd.
Donggang Wanrui Food Co., Ltd. lacked required seafood safety plan monitoring and records for raw frozen octopus and crab.
High risk -
FoodSakhon Wattana Thang Chue Hah
FDA warns Thai fish sauce maker Sakhon Wattana Thang Chue Hah over missing safety controls for pathogens and histamine.
High risk -
DrugsAruba Aloe Balm N.V.
Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.
High risk -
DrugsNatuzen Co., Ltd.
Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.
High risk -
DrugsVintage Chemical Inc.
FDA warned Vintage Chemical after an inspection found over-the-counter hand soap and sanitizer made on equipment shared with industrial cleaners.
High risk -
DrugsMaster Paints & Chemicals Corp.
FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
High risk -
DrugsFirstCham Co., Ltd.
FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.
High risk -
DrugsColgin, Inc.
FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.
High risk -
DrugsNantong Furuida Packaging Products Co., Ltd.
Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.
High risk -
DrugsXiamen Wally Bath Manufacture Co., Ltd.
FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.
High risk -
DrugsSaruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi
FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.
High risk -
DrugsGreen Pharmaceutical Co. Ltd.
FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.
High risk -
DrugsLaavo Clean, S.A. de C.V.
Laavo Clean's alcohol-free hand sanitizers had wrong benzalkonium chloride strength and were refused at US border.
High risk -
DrugsFancystage Unipessoal, LDA
Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.
High risk -
FoodManzanola Feeds, LLC
Manzanola Feeds' alfalfa horse cubes contained Clostridium botulinum toxin type C and animal hair, causing an outbreak and recall.
High risk -
DrugsSkyless, LLC
FDA cited Skyless, LLC for CGMP failures and for selling three X-PASMO topical analgesic ointments as unapproved and misbranded drugs.
High risk -
DevicesGetsch+Hiller Medizintechnik GmbH
FDA warned Getsch+Hiller about unapproved reusable laparoscopic tips and missing quality records at its German plant.
High risk -
DrugsSalon Technologies International, Inc.
FDA warns Salon Technologies International that its hand sanitizers contained unacceptable acetaldehyde, acetal and benzene impurities and were adulterated.
High risk -
DrugsMcConnell Labs Inc.
McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.
High risk -
DrugsDDI Multinacional S.A. de C.V.
DDI Multinacional hand sanitizers labeled 70% ethanol contained up to 60% methanol, leading to adulteration and import alert.
High risk -
DrugsIndustrias Cklass S. de R.L. de C.V.
FDA found Industrias Cklass hand sanitizer labeled 70% ethanol contained 19% ethanol and 48% methanol and was refused U.S. admission.
High risk -
DrugsDavid Cosmetic Co., Ltd.
FDA lab testing found benzene, a cancer-causing impurity, at about 6 ppm in David Cosmetic's CALA hand sanitizer, making it adulterated.
High risk -
DrugsMaquiladora Miniara SA de CV
Maquiladora Miniara's Shine and clean Hand Sanitizer Gel was found to contain methanol instead of labeled ethanol.
High risk -
DrugsBionateo Sp. z.o.o.
Bionateo, a Polish drugmaker, shipped hand sanitizer contaminated with methanol and isopropanol that FDA refused at the U.S. border.
High risk -
DrugsAriBio H&B Co., Ltd.
FDA warns AriBio H&B over subpotent Hand Sanitizer Original labeled 70% ethanol but tested at 58%, plus misbranding.
High risk